- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02865629
N-acetylcysteine in the Treatment of Depressive Symptoms in Bipolar Offspring
May 7, 2018 updated by: Fabiano Nery, University of Cincinnati
N-acetylcysteine in the Treatment of Depressive Symptoms in Youth at High-risk for Bipolar Disorder: a Functional Connectivity Study
N-acetylcysteine in the treatment of depressive symptoms in youth at high-risk for bipolar disorder: a functional connectivity study
Study Overview
Detailed Description
To conduct an 8-week, open label study of N-acetylcysteine for the treatment of depressive symptoms in youth at high risk for bipolar disorder, with resting state functional magnetic resonance imaging (fMRI) examinations at baseline and endpoint.
This proposal is innovative because it investigates the efficacy and tolerability of a novel pharmacological treatment in youth offspring of bipolar disorder, and examines the neurophysiology of predictors of mood disorders in youth at high risk for bipolar disorder.
This study will obtain pilot data to propose a larger, neuroimaging-based, double-blind, placebo-controlled trial of N-acetylcysteine in youth at high risk for bipolar disorder.
The expected outcome, that N-acetylcysteine will be efficacious in ameliorating depressive symptoms in youth at high risk for bipolar disorder, and that it will demonstrate improvement in functional connectivity within the left frontostriatal circuit associated with treatment response.
Study Type
Interventional
Enrollment (Anticipated)
22
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fabiano G. Nery, MD, PhD
- Phone Number: 513.558.5035
- Email: neryfo@email.uc.edu
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience
-
Contact:
- Stephanie Schaeper, B.S.
- Phone Number: 513-558-5953
- Email: schaepsi@ucmail.uc.edu
-
Principal Investigator:
- Fabiano Nery, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 24 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion:
- Male or female subjects 15 years, 0 months - 24 years, 11 months of age at screening
- For minor, at least one parent or step-parent/guardian with whom the subject lives is willing to participate in research sessions
- For minor, the child and relative(s) are able and willing to give written informed assent/consent to participate, respectively
- Subject has at least one first degree relative with Bipolar I Disorder, as assessed by the Structured Clinical Interview for DSM (SCID) or the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS-PL)
- Subject shows evidence of current significant depressive symptoms as determined by a current Hamilton Depression Rating Scale (HAM-D) greater or equal to 8
Exclusion:
- Patient has presence of current or lifetime history of manic or hypomanic mood episodes, psychotic disorders including schizophrenia, current major depressive episode, and/or more than two prior major depressive episodes
- Patient has a DSM-5 diagnosis of autism, pervasive developmental disorder, OCD, PTSD, or Tourette's disorder
- Patient has drug or alcohol abuse or dependence disorders in the three months prior to study recruitment, although a lifetime history of substance or alcohol disorders can be present if the patient has been abstinent for at least three months
- Pregnancy; participants will be encouraged but not mandated to discuss a positive pregnancy test with their guardians (if minors) and we will follow local laws
- Patient has history of major neurological disorders (such as epilepsy), or head trauma with > 10 minutes loss of consciousness
- Patient has evidence of mental retardation (IQ less than 70), as determined by the Wechsler Abbreviated Scale of Intelligence (WASI)
- Patient has any contraindication for MRI, including metal in the body related to an injury or surgery (e.g., surgical clips, metal fragments in the eyes), piercings that cannot be removed, or braces
- Patient has history of allergic reaction to N-acetylcysteine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: N-acetyl cysteine
Following the screening and review of all laboratory studies, patients will be scheduled to receive N-acetylcysteine.
|
N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8.
Doses might be decreased anytime if clinically indicated.
Following the study, all patients will be referred to treatment as usual.
Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month.
Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton Depression Rating Scale (HAM-D) scores
Time Frame: Baseline to endpoint (8 weeks)
|
The primary outcome will be change in depressive symptoms, as measured by HAMD scores, from baseline to endpoint.
|
Baseline to endpoint (8 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Young Mania Rating Scale (YMRS) scores
Time Frame: Baseline to endpoint (8 weeks)
|
A secondary outcome will be change in manic symptom, measured by YMRS scores, from baseline to endpoint.
|
Baseline to endpoint (8 weeks)
|
Hamilton Anxiety Rating Scale (HAM-A) scores to measure anxiety symptoms
Time Frame: Baseline to endpoint (8 weeks)
|
A secondary outcome will be change anxiety symptoms, as measured by HAM-A scores, from baseline to endpoint.
|
Baseline to endpoint (8 weeks)
|
Clinical Global Impression of Severity (CGI-S) scores
Time Frame: Baseline to endpoint (8 weeks)
|
A secondary outcome will be change in subjects' overall clinical condition, as measured by CGI-S scores, from baseline to endpoint.
|
Baseline to endpoint (8 weeks)
|
Connectivity index, as defined by the temporal bivariate correlation between fMRI signal fluctuations in the left ventrolateral prefrontal cortex and the left striatum
Time Frame: Baseline to endpoint (8 weeks)
|
A secondary outcome will be change in functional connectivity, as measured by the connectivity index, between the left ventrolateral prefrontal cortex and the left striatum from baseline to endpoint.
The connectivity index is defined as the temporal bivariate correlation between fMRI signal fluctuations in the 2 regions of interest.
|
Baseline to endpoint (8 weeks)
|
Correlation between change in depressive symptoms and change in connectivity index
Time Frame: Baseline to endpoint (8 weeks)
|
A secondary outcome will be correlation between changes in depressive symptoms and changes in functional connectivity, as measured by the connectivity index, between the left ventrolateral prefrontal cortex and left striatum from baseline to endpoint.
The connectivity index is defined as the temporal bivariate correlations between fMRI signal fluctuations in the 2 regions of interest.
|
Baseline to endpoint (8 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Fabiano G. Nery, MD, PhD, University of Cincinnati
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2016
Primary Completion (Anticipated)
August 1, 2019
Study Completion (Anticipated)
September 1, 2019
Study Registration Dates
First Submitted
June 28, 2016
First Submitted That Met QC Criteria
August 9, 2016
First Posted (Estimate)
August 12, 2016
Study Record Updates
Last Update Posted (Actual)
May 14, 2018
Last Update Submitted That Met QC Criteria
May 7, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Nery UCNI NAC study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on N-acetyl cysteine
-
Universidade Estadual de MaringáUnknownBipolar DisorderBrazil
-
Minia UniversityUnknown
-
University of Colorado, DenverWithdrawn
-
Aga Khan UniversityNational Institute of Liver & GI Diseases, PakistanNot yet recruiting
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnHead and Neck Cancer
-
Ain Shams UniversityRecruiting
-
Imam Khomeini HospitalTehran Heart CenterUnknownRadiographic Contrast Agent Nephropathy | Chronic Kidney Disease Stage 2Iran, Islamic Republic of
-
Nemours Children's ClinicCompletedObesity | Cardiovascular Disease | Nonalcoholic Fatty Liver DiseaseUnited States
-
Washington University School of MedicineSuspendedDiabetes Mellitus | Peripheral Arterial Disease | Critical Limb Ischemia | Lower Limb Amputation KneeUnited States
-
Children's Hospital Medical Center, CincinnatiUnited States Department of DefenseRecruitingNeurofibromatosis 1United States